267 related articles for article (PubMed ID: 26530264)
1. Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Nahed BV; Redjal N; Brat DJ; Chi AS; Oh K; Batchelor TT; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):609-30. PubMed ID: 26530264
[TBL] [Abstract][Full Text] [Related]
2. The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
Ziu M; Kalkanis SN; Gilbert M; Ryken TC; Olson JJ
J Neurooncol; 2015 Dec; 125(3):585-607. PubMed ID: 26530261
[TBL] [Abstract][Full Text] [Related]
3. The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Aghi MK; Nahed BV; Sloan AE; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):503-30. PubMed ID: 26530265
[TBL] [Abstract][Full Text] [Related]
4. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
5. The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Ryken TC; Parney I; Buatti J; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):551-83. PubMed ID: 26530266
[TBL] [Abstract][Full Text] [Related]
6. The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Fouke SJ; Benzinger T; Gibson D; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):457-79. PubMed ID: 26530262
[TBL] [Abstract][Full Text] [Related]
7. The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Cahill DP; Sloan AE; Nahed BV; Aldape KD; Louis DN; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):531-49. PubMed ID: 26530263
[TBL] [Abstract][Full Text] [Related]
8. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Bady P; Kurscheid S; Delorenzi M; Gorlia T; van den Bent MJ; Hoang-Xuan K; Vauléon É; Gijtenbeek A; Enting R; Thiessen B; Chinot O; Dhermain F; Brandes AA; Reijneveld JC; Marosi C; Taphoorn MJB; Wick W; von Deimling A; French P; Stupp R; Baumert BG; Hegi ME
Acta Neuropathol; 2018 Apr; 135(4):601-615. PubMed ID: 29368212
[TBL] [Abstract][Full Text] [Related]
9. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
10. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L
Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415
[TBL] [Abstract][Full Text] [Related]
11. To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.
Paľa A; Coburger J; Scherer M; Ahmeti H; Roder C; Gessler F; Jungk C; Scheuerle A; Senft C; Tatagiba M; Synowitz M; Wirtz CR; Schmitz B; Unterberg AW
J Neurosurg; 2019 Jul; 133(2):273-280. PubMed ID: 31323633
[TBL] [Abstract][Full Text] [Related]
12. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
14. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
15. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
16. Current management of low-grade gliomas.
Hottinger AF; Hegi ME; Baumert BG
Curr Opin Neurol; 2016 Dec; 29(6):782-788. PubMed ID: 27676279
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Yu Y; Villanueva-Meyer J; Grimmer MR; Hilz S; Solomon DA; Choi S; Wahl M; Mazor T; Hong C; Shai A; Phillips JJ; Wainer BH; McDermott M; Haas-Kogan D; Taylor JW; Butowski N; Clarke JL; Berger MS; Molinaro AM; Chang SM; Costello JF; Oberheim Bush NA
Neuro Oncol; 2021 Nov; 23(11):1872-1884. PubMed ID: 33823014
[TBL] [Abstract][Full Text] [Related]
19. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
Abrigo JM; Fountain DM; Provenzale JM; Law EK; Kwong JS; Hart MG; Tam WWS
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011551. PubMed ID: 29357120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]